Home/Biosimilar Atlas/Bevacizumab/Reliance Life Sciences bevacizumab

Reliance Life Sciences bevacizumab

Bevacizumab biosimilar developed by Reliance Life Sciences. Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOJan 2016permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
BevacizumabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer7rival developers in its markets

About Reliance Life Sciences bevacizumab

Reliance Life Sciences holds the first bevacizumab permission granted anywhere in the world, in India in January 2016, over a year before the first Western approval. It was permitted initially for bowel cancer, and liver cancer in combination with another antibody was added in 2023.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Jan 2016
Application or permission
MF-48/2016; BULK-49/2016; additional indication MF/BIO/23/000098
Indications as licensed
Metastatic colorectal cancer at permission; hepatocellular carcinoma with atezolizumab added November 2023
Presentations
100 mg/4 mL and 400 mg/16 mL
Remarks
First bevacizumab biosimilar permitted anywhere.
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO7Biocon Biologics (Jobevne / Abevmy / Krabeva), CuraTeQ Biologics (CuraTeQ bevacizumab), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Zydus Lifesciences (Zydus bevacizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.